You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Tafluprost - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for tafluprost and what is the scope of patent protection?

Tafluprost is the generic ingredient in two branded drugs marketed by Micro Labs, Sandoz, and Thea Pharma, and is included in three NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Tafluprost has eighty patent family members in twenty-six countries.

There are three drug master file entries for tafluprost. Four suppliers are listed for this compound.

Drug Prices for tafluprost

See drug prices for tafluprost

Recent Clinical Trials for tafluprost

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fondazione G.B. Bietti, IRCCSPhase 4
Tun Hussein Onn National Eye HospitalPhase 4
Taejoon Pharmaceutical Co., Ltd.Phase 4

See all tafluprost clinical trials

Pharmacology for tafluprost
Paragraph IV (Patent) Challenges for TAFLUPROST
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZIOPTAN Ophthalmic Solution tafluprost 0.0015% 202514 2 2016-02-10

US Patents and Regulatory Information for tafluprost

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz TAFLUPROST tafluprost SOLUTION/DROPS;OPHTHALMIC 209040-001 Jan 28, 2022 AT RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Micro Labs TAFLUPROST tafluprost SOLUTION/DROPS;OPHTHALMIC 209051-001 Aug 19, 2019 AT RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Thea Pharma ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 AT RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Thea Pharma ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 AT RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for tafluprost

Country Patent Number Title Estimated Expiration
South Korea 101650006 ⤷  Try a Trial
Georgia, Republic of P20156220 COMPOSITION TREATING OCULAR HYPERTENSION AND GLAUCOMA, AND USAGE THEREOF ⤷  Try a Trial
Slovenia 2306977 ⤷  Try a Trial
Slovenia 2772249 ⤷  Try a Trial
Jordan 3039 طريقة ومركب لعلاج فرط ضغط العين والجلوكوما (Method and composition for treating ocular hypertension and Glaucoma) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for tafluprost

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0850926 11C0020 France ⤷  Try a Trial PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE IN FRANCE: CIS:6 000 728 O DU 20110328; REGISTRATION NO/DATE AT EEC: 43230 DU 20080430
0850926 SPC/GB09/005 United Kingdom ⤷  Try a Trial PRODUCT NAME: TAFLUPROST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: DK 43230 20080430; UK PL 16058/0011-0001 20081017
0850926 C00850926/01 Switzerland ⤷  Try a Trial PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE: SWISSMEDIC 60548 27.01.2010
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.